Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Noventra Labs R3t@trutide 32 mg

R 2,240.00 R 2,080.00
Add to WishlistCompare

Noventra Pharma R3t@trutide 32 mg — Multidose Pen

Triple-Receptor Research | Metabolic Health | Weight-Management Research

Product Overview

Noventra Pharma R3t@trutide 32 mg Multidose Pen is a pre-filled pen-format product labelled with a total strength of 32 mg and a 200-click mechanism.

R3t@trutide is an investigational compound attracting considerable scientific interest for its unique activity across three metabolic hormone receptors: GLP-1, GIP and glucagon. These pathways are being studied for their roles in appetite signalling, energy balance, glucose regulation and body-weight changes.

The multidose pen format offers a compact, integrated presentation, with the product packaging specifying a multi-dose pen design and single-patient use.

Key Research Findings

Clinical studies have reported promising results for retatrutide in adults living with obesity.

  • Significant body-weight reduction: In a Phase 2 clinical trial, the group receiving the highest studied dose experienced an average body-weight reduction of 24.2% after 48 weeks.

  • Reduced waist circumference: Participants experienced reductions in waist circumference across the studied treatment groups.

  • Metabolic markers: Researchers observed improvements in several cardiometabolic measures, including blood glucose, HbA1c, blood pressure and certain lipid measurements.

  • Triple-receptor mechanism: Retatrutide activates GLP-1, GIP and glucagon receptors, making it a distinctive subject of ongoing metabolic research.

Key Features
  • Noventra Pharma pen format with a labelled strength of 32mg.
  • Contains r3t@trutide (LY3437943), an investigational peptide.
  • Triple-receptor research focus involving GLP-1, GIP, and glucagon pathways.
  • Scientific interest in metabolic signalling, glucose regulation, appetite regulation, and energy expenditure.
  • Published research includes investigation of body-weight and body-composition outcomes.

Research findings do not verify the contents, quality, safety, or effectiveness of this specific pen. Confirm product specifications using the manufacturer’s documentation.

Dosage & Usage

Week 1: 1.5 mg — 10 clicks

Week 2: 3.0 mg — 20 clicks

Week 3: 4.5 mg — 30 clicks

Week 4: 6.0 mg — 40 clicks

Week 5 (Maintenance): 7.5 mg — 50 clicks

Week 6: 9.0 mg — 60 clicks

Week 7: 10.5 mg — 2 × 35 clicks

Week 8 (Maximum): 12.0 mg — 2 × 40 clicks

FAQ's & Tips

1. What is the Noventra Pharma Retatrutide 32mg Pen?

It is a Noventra Pharma product presented in a pen format with a labelled strength of 32mg of retatrutide. Consult the manufacturer’s documentation to confirm the total contents and product specifications.

2. What is retatrutide?

Retatrutide is an investigational peptide studied for its activity across three receptor pathways: GLP-1, GIP, and glucagon. This is commonly described as a triple-receptor agonist approach.

3. What is retatrutide being researched for?

Research examines metabolic signalling, glucose regulation, appetite regulation, energy expenditure, and body-weight outcomes. Findings about the compound do not establish the safety or effectiveness of this specific branded pen.

4. Does 32mg refer to a single dose?

Do not interpret the product’s labelled strength as a dosing instruction. Confirm what the 32mg designation represents using the manufacturer’s documentation.

5. How should the pen be stored?

Follow the storage conditions and expiry information printed on the product packaging or supplied by the manufacturer. Do not assume storage requirements from those of other peptide products.

6. Are dosing or administration instructions provided?

This page does not provide dosing, injection, or self-administration instructions. Product information should not be used as a substitute for advice from a qualified healthcare professional.

7. Where can I find more information about retatrutide research?

Consult peer-reviewed scientific publications and registered clinical-trial records. Distinguish research on retatrutide from evidence verifying the contents, quality, or suitability of a particular commercial product.

Research

Research Overview

r3t@trutide (LY3437943) is an investigational peptide studied as a triple agonist targeting GLP-1, GIP, and glucagon receptors. Research explores how activity across these three pathways influences metabolic signalling and related physiological processes.

Areas of Research

Scientific studies examine glucose regulation, appetite regulation, energy expenditure, and changes in body weight and body composition. Ongoing investigation also evaluates safety, tolerability, and longer-term outcomes.

Published Research

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972.

This trial investigated r3t@trutide in adults with obesity over 48 weeks. Consult the original publication for study methods, findings, adverse events, and limitations.

Important Research Context

Published studies concern the investigational compound used under controlled clinical-trial conditions. They do not verify the identity, purity, stability, safety, or effectiveness of the Noventra Pharma 32mg Pen. This information is educational and does not provide dosing or administration guidance.

Reviews